PleXus Communications

PleXus Communications: Delivering quality online CME/CE accredited activities to meet the educational needs of oncology and hematology healthcare providers.

 

PleXus Communications
B

Why We Should Not Treat SMM

By PleXus Communications FEATURING Ben Derman
By PleXus Communications FEATURING Ben Derman
414 views
November 27, 2023
0 Comments
Login to view comments. Click here to Login
Videos
32:49
PleXus Communications

Myeloma Rounds: Asymptomatic Patient With High-Risk SMM

Feat. N. Antao, P. Hagen
04:28
PleXus Communications

Myeloma Rounds: Patient With SMM Enrolled in the DETER-SMM Trial

Feat. N. Antao
28:20
PleXus Communications

Why We Should Not Treat SMM

Feat. B. Derman
28:30
PleXus Communications

Adverse Effects of Treatment for mCSPC and Their Multidisciplinary M…

Feat. G. Cullen
43:34
PleXus Communications

Advancing Care for Veterans: No Longer Settling for "Enough&quo…

Feat. M. Rettig
42:02
PleXus Communications

Improving Bladder Cancer Outcomes by Integrating New Knowledge Into …

Feat. M. Galsky
33:44
PleXus Communications

Low-Risk MDS in Community Practice: How Recent Advances Will Benefit…

Feat. G. Garcia-Manero
53:01
PleXus Communications

Changing Pharmacological Paradigms for Higher-Risk Myelofibrosis

Feat. R. Rampal
55:14
PleXus Communications

Exploring the Evolving and Expanding Role of CAR T-Cell Therapies in…

Feat. J. Abramson
53:42
PleXus Communications

Managing Women's Health in Menopause: Evolving Approaches for t…

Feat. J. Simon, T. Iyer, A. Fiffick, M. Minkin
50:10
PleXus Communications

Optimizing Androgen Deprivation Therapy in Advanced Prostate Cancer

Feat. N. Shore
29:38
PleXus Communications

Fine Tuning Anti-BCMA Therapies in MM

Feat. J. Cooperrider
28:05
PleXus Communications

Infections in Patients With MM in the Modern Era

Feat. A. Han
38:44
PleXus Communications

Evolving Clinical Perspectives for High-Risk and R/R AML Management

Feat. A. Zeidan
43:53
PleXus Communications

Clinical Practices for Optimizing the Use of BTK Inhibitors for the …

Feat. M. Davids
33:30
PleXus Communications

Treatment Intensification Strategies to Improve Outcomes of Patients…

Feat. J. Graff
39:25
PleXus Communications

Adverse Effects of Treatment for mHSPC and Their Multidisciplinary M…

Feat. G. Cullen
07:36
PleXus Communications

Diagnosis and Risk Stratification Considerations for MM

Feat. A. Krishnan
27:55
PleXus Communications

Evolving Concepts of Managing Newly Diagnosed Multiple Myeloma Patie…

Feat. O. Landgren
20:35
PleXus Communications

Relapsed and Refractory MM: Choosing the Right Treatment

Feat. S. Lonial
08:54
PleXus Communications

CAR T-Cell Therapy for Relapsed MM

Feat. A. Krishnan
43:03
PleXus Communications

Advances in Targeted Therapies for NSCLC: Optimizing Patient Outcomes

Feat. M. Das
40:37
PleXus Communications

B-Cell Non-Hodgkin Lymphomas: Integrating Recent Treatment Advances …

Feat. I. Flinn
53:23
PleXus Communications

Recent Advances and Evidence-Based Clinical Practices to Optimize Ca…

Feat. S. Jain
45:42
PleXus Communications

The Evolving Treatment Landscape for Higher-Risk MDS

Feat. J. Shammo
54:58
PleXus Communications

Expert Perspectives on Treating High-Risk and R/R AML

Feat. E. Stein
51:44
PleXus Communications

Management of Waldenstrom's Macroglobulinemia in the Era of Tar…

Feat. S. Treon
44:24
PleXus Communications

Optimizing the Care of Mantle Cell Lymphoma: Translating the Latest …

Feat. J. Cohen
56:26
PleXus Communications

Advances in CAR T-Cell Therapies: Optimizing Outcomes and Implementa…

Feat. C. Jacobson
59:33
PleXus Communications

Understanding Evoloving Treatment Strategies in NDMM Patients

Feat. B. Derman
54:30
PleXus Communications

Expert Perspectives on Optimizing Outcomes With the Latest Advances …

Feat. M. Davids
45:05
PleXus Communications

Shifting Paradigms in the Management of Advanced Urothelial Carcinoma

Feat. U. Vaishampayan
60:02
PleXus Communications

2022 Updates on Navigating the Continuum of Care for Advanced Prosta…

Feat. M. Rettig
48:34
PleXus Communications

Emerging Cellular and Targeted Therapy Options for the Management of…

Feat. C. Jacobson
53:46
PleXus Communications

HR+ Breast Cancer: Individualizing Therapy With CDK 4/6 Inhibitors

Feat. K. Jhaveri